TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30053956

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI; 100/25 or 200/25 μg)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 423
Study: 26536441

Group type: EXPERIMENTAL
Intervention: Aspen collar
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Miami J standard collar
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aspen Vista collar
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Miami J Advanced collar
Number of subjects: 48

Group type: COMPARATOR
Intervention: No collar
Number of subjects: 48
Study: 25274615

Group type: EXPERIMENTAL
Intervention: Bevacizumab 5 mg/kg with WBRT (30 Gy/15 fractions/3 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg with WBRT (30 Gy/15 fractions/3 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg with WBRT (30 Gy/10 fractions/2 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Overall treatment (Bevacizumab combined with WBRT)
Number of subjects: 19
Study: 21170682

Group type: EXPERIMENTAL
Intervention: Health Education Attention Condition (HEAC)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Interpersonal Counseling Intervention (TIP-C)
Number of subjects: 141
Study: 19647405

Group type: EXPERIMENTAL
Intervention: Noninvasive coronary flow reserve (CFR) assessment using intravenous adenosine infusion
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Noninvasive coronary flow reserve (CFR) assessment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: CFR cutoff value of 1.7
Number of subjects: 55
Study: 17284138

Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole 9.75 mg
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole 5.25 mg
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole 15 mg
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol 7.5 mg
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 16036077

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: One specific HRT regimen from the Women's Health Initiative
Number of subjects: 0
Study: 12571942

Group type: EXPERIMENTAL
Intervention: Dibutyl phthalate
Number of subjects: 143

Group type: COMPARATOR
Intervention: New fumanling cream
Number of subjects: 143
Study: 9701104

Group type: EXPERIMENTAL
Intervention: Walking intervention
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study: 7881859

Group type: EXPERIMENTAL
Intervention: Antimicrobial insoles (furagin, nitrofurilacroleine, polyhexamethylene guanidine) applied for 2 weeks
Number of subjects: 32
Study: 3065158

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) (n = 48)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment (ICT) (n = 41)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Conventional treatment (CT) (n = 28)
Number of subjects: 189
Study: 31782347

Group type: EXPERIMENTAL
Intervention: Individualized ICT training program for older adults
Number of subjects: 85
Study: 29987919

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 5081
Study: 25963381

Group type: EXPERIMENTAL
Intervention: Support group
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Telephone group
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 336
Study: 25591726

Group type: EXPERIMENTAL
Intervention: Three-dimensional rotational angiography (3DRA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard fluoroscopic views (SFV)
Number of subjects: 60
Study: 23663752

Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg BID
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: All apremilast doses
Number of subjects: 352
Study: 20954763

Group type: EXPERIMENTAL
Intervention: Family Foundations intervention (a series of eight classes delivered before and after birth)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Family Foundations intervention
Number of subjects: 169
Study: 19192663

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus CIK cell transfusion
Number of subjects: 59

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 59
Study: 16495372

Group type: EXPERIMENTAL
Intervention: APC 1 with Transbond Plus Self‐Etching Primer (TPSEP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: APC 2 with Transbond Plus Self‐Etching Primer (TPSEP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Victory Series (V) brackets with Transbond Plus Self‐Etching Primer (TPSEP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Victory Series (V) brackets with 37 percent phosphoric acid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: APC 1, APC 2, and V brackets (all types) for shear rebond strengths
Number of subjects: 120
Study: 12958052

Group type: EXPERIMENTAL
Intervention: Physostigmine (PHYS) 0.12 microg/minute/kg, 7-hour infusion
Number of subjects: 10
Study: 11127567

Group type: EXPERIMENTAL
Intervention: Combined clear cornea phacoemulsification and trabecular aspiration
Number of subjects: 27

Group type: COMPARATOR
Intervention: Clear cornea phacoemulsification alone
Number of subjects: 27
Study: 9417492

Group type: EXPERIMENTAL
Intervention: Selenium treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no selenium treatment)
Number of subjects: 28
Study: 1359681

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study: 3472452

Group type: EXPERIMENTAL
Intervention: Regular exercise training for 12 weeks
Number of subjects: 34
Study: 31227662

Group type: EXPERIMENTAL
Intervention: c‐AFO
Number of subjects: 16

Group type: COMPARATOR
Intervention: Shoe walking
Number of subjects: 16
Study: 30219886

Group type: EXPERIMENTAL
Intervention: 1-year trastuzumab plus chemotherapy (arm A, long)
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: 9 weeks trastuzumab plus chemotherapy (arm B, short)
Number of subjects: 1254
Study: 26369284

Group type: EXPERIMENTAL
Intervention: Rapid advancement (36 ml/kg/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High initiation (24 ml/kg/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low initiation (4 ml/kg/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low advancement (24 ml/kg/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High advancement (36 ml/kg/day)
Number of subjects: 200
Study: 24585432

Group type: EXPERIMENTAL
Intervention: Moxilen®
Number of subjects: 18

Group type: COMPARATOR
Intervention: YSP Amoxicillin® capsule
Number of subjects: 18
Study: 22909146

Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride topical gel (OTG) 10% applied once daily (1g, 100mg oxybutynin)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Immediate-release oxybutynin (OXB-IR) 5mg capsule three times/day
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 20575621

Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine 1.3% topical patch (DETP) applied once daily for 7 days
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 274
Study: 17900227

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 86

Group type: COMPARATOR
Intervention: Brimonidine Purite 0.15%
Number of subjects: 86
Study: 15138297

Group type: EXPERIMENTAL
Intervention: FTY720 1 mg alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cyclosporine 200 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: FTY720 1 mg with cyclosporine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cyclosporine with FTY720
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FTY720 alone and with cyclosporine
Number of subjects: 12
Study: 11585480

Group type: EXPERIMENTAL
Intervention: Weekly administration of antenatal corticosteroids (betamethasone, 12 mg intramuscularly repeated once in 24 hours for 2 doses every week until 34 weeks' gestation or delivery)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Single course of antenatal corticosteroids (either betamethasone, 12 mg intramuscularly repeated once in 24 hours for 2 doses, or dexamethasone, 6 mg intramuscularly repeated every 12 hours for 4 doses)
Number of subjects: 502
Study: 9664917

Group type: EXPERIMENTAL
Intervention: Diet A (average American diet) providing 37% of energy from fat, 16% from saturated fatty acids (SFAs)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Diet B (step 1 diet) providing 30% of energy from fat, 9% from SFA
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Diet C (low SFA diet) providing 26% of energy from fat, 5% from SFA
Number of subjects: 103
Study: 7656916

Group type: EXPERIMENTAL
Intervention: Wine consumption with dinner
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mineral water consumption with dinner
Number of subjects: 8
Study: 2695152

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 1328
Study: 855849

Group type: EXPERIMENTAL
Intervention: Bismuth subgallate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Codeine sulfate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Deodorized tincture of opium (DTO)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diphenoxylate (Lomotil)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fat excretion
Number of subjects: 6
Study: 31780395

Group type: EXPERIMENTAL
Intervention: CT‐lungNET
Number of subjects: 173
Study: 30707361

Group type: EXPERIMENTAL
Intervention: Botulinum toxin 50 U
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Botulinum toxin 100 U
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Repeat Botulinum toxin 100 U injections
Number of subjects: 33
Study: 28658172

Group type: EXPERIMENTAL
Intervention: Electric blanket plus forced-air warming system (group EF)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Regular blanket plus electric blanket (group E)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Regular blanket (group C)
Number of subjects: 346
Study: 26224390

Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting stent (PES = Coroflex Please, B.Braun)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Bare metal stent (BMS = Coroflex) followed by paclitaxel coated balloon (PCB = Sequent Please, B.Braun)
Number of subjects: 202

Group type: COMPARATOR
Intervention: BMS + PCB
Number of subjects: 202
Study: 24226381

Group type: EXPERIMENTAL
Intervention: Tropisetron and metoclopramide (Group II)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate and dexamethasone (Group III)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Tropisetron as a single medication (Group IV)
Number of subjects: 308

Group type: COMPARATOR
Intervention: No prophylaxis (Group I)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 308
Study: 21113820

Group type: EXPERIMENTAL
Intervention: Self-monitoring measures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-assessment
Number of subjects: 0
Study: 19526613

Group type: EXPERIMENTAL
Intervention: Leucocyte-depleted (LD) RBC transfusion
Number of subjects: 512

Group type: COMPARATOR
Intervention: Non-leucocyte-depleted (non-LD) RBC transfusion
Number of subjects: 512
Study: 17275889

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin and pelvic radiation (GOG 120)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin and pelvic radiation (GOG 165)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Prolonged radiation (GOG 165)
Number of subjects: 335
Study: 15942776

Group type: EXPERIMENTAL
Intervention: Flatfoot deformity stage 2 patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Surgical strategies including stage 2 soft tissue reconstruction and hindfoot osteotomies combined with hindfoot arthrodeses (subtalar fusion)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Patients with no hindfoot malalignment
Number of subjects: 150
Study: 11831543

Group type: EXPERIMENTAL
Intervention: lovastatin immediate-release (IR) 40 mg tablets following a standard breakfast
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: lovastatin extended-release (ER) 40 mg tablets following a standard breakfast
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: lovastatin extended-release (ER) 40 mg tablets under fasting conditions
Number of subjects: 9

Group type: COMPARATOR
Intervention: lovastatin extended-release (ER) tablets with breakfast
Number of subjects: 9
Study: 10037132

Group type: EXPERIMENTAL
Intervention: Filtered blood transfusion
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonfiltered blood transfusion
Number of subjects: 52
Study: 7728285

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g/d)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 2140332

Group type: EXPERIMENTAL
Intervention: Topical tetracycline applied twice daily for 16 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 16 weeks
Number of subjects: 85
Study: 6101956

Group type: COMPARATOR
Intervention: Clorazepate dipotassium 5 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Clorazepate dipotassium 7.5 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Clorazepate dipotassium 15 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Clorazepate dipotassium 7.5 mg/day for 14 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Clorazepate dipotassium 15 mg/day for 14 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 29889653

Group type: EXPERIMENTAL
Intervention: Barefoot running for 20 minutes
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Shod running for 20 minutes
Number of subjects: 26
Study: 28100321

Group type: EXPERIMENTAL
Intervention: Esmolol treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 102
Study: 26015434

Group type: EXPERIMENTAL
Intervention: euinsulinemia-hyperglycemia
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: hyperinsulinemia-hyperglycemia
Number of subjects: 22

Group type: COMPARATOR
Intervention: euinsulinemia-euglycemia
Number of subjects: 22

Group type: COMPARATOR
Intervention: hyperinsulinemia-euglycemia
Number of subjects: 22
Study: 24236810

Group type: EXPERIMENTAL
Intervention: Peer modeling intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 21331628

Group type: EXPERIMENTAL
Intervention: Functional beverage rich in vitamins C and E plus Lippia citriodora extract (PLX) containing 20 mg/100 ml verbascoside
Number of subjects: 10

Group type: COMPARATOR
Intervention: Functional beverage rich in vitamins C and E (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Functional beverage rich in vitamins C and E plus Lippia citriodora extract (PLX)
Number of subjects: 10
Study: 19726396

Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy regimens (dose‐dense taxane, dose‐standard taxane, or dose‐standard without taxane)
Number of subjects: 196
Study: 17056201

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg by mouth twice per day for 2 weeks before and during CRT
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Celecoxib administration before CRT
Number of subjects: 31
Study: 15163253

Group type: EXPERIMENTAL
Intervention: Beaded extended-release carbamazepine capsules (ERC-CBZ; SPD417) 200-1600 mg/day, mean dose 938 mg/day
Number of subjects: 92
Study: 11171831

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ligation
Number of subjects: 80
Study: 9877150

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate ingestion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8027144

Group type: EXPERIMENTAL
Intervention: Calcium heparin
Number of subjects: 132

Group type: COMPARATOR
Intervention: A‐V Impulse System (intermittent plantar pump)
Number of subjects: 132
Study: 2644898

Group type: EXPERIMENTAL
Intervention: Total Gastrectomy (TG)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Subtotal Gastrectomy (SG)
Number of subjects: 169
Study: 182445

Group type: EXPERIMENTAL
Intervention: Sitosterol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sitosterol + lipid lowering diet
Number of subjects: 14
Study: 31112561

Group type: EXPERIMENTAL
Intervention: Half-squat (HS) exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cycle ergometer exercise
Number of subjects: 18
Study: 28642125

Group type: EXPERIMENTAL
Intervention: VIM-only stimulation for 3 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: VO-only stimulation for 3 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both leads activated after initial 3 months
Number of subjects: 12
Study: 25411413

Group type: EXPERIMENTAL
Intervention: Combined dabrafenib and trametinib therapy (CombiDT) at standard dose (150/2)
Number of subjects: 201
Study: 23392000

Group type: EXPERIMENTAL
Intervention: Individualized CDKN2A and MC1R genotyping results in the context of a genetic counseling session
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard practice of not being offered counseling or disclosure of genotyping results
Number of subjects: 73
Study: 21698100

Group type: EXPERIMENTAL
Intervention: Acetaminophen (10-15 mg per kg)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 19490462

Group type: EXPERIMENTAL
Intervention: ketamine 0.15 mg/kg i.v.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ketamine 0.15 mg/kg + midazolam 0.01 mg/kg i.v.
Number of subjects: 60

Group type: COMPARATOR
Intervention: saline control
Number of subjects: 60
Study: 16338907

Group type: EXPERIMENTAL
Intervention: Endurance exercise (1 h of cycling at 70% peak O2 uptake)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Resistance exercise (8 x 5 maximal leg extensions)
Number of subjects: 13
Study: 14718319

Group type: EXPERIMENTAL
Intervention: High amount/vigorous intensity (20 miles jogging/week at 65%-80% peak oxygen consumption)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Low amount/vigorous intensity (12 miles jogging/week at 65%-80% peak oxygen consumption)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Low amount/moderate intensity (12 miles walking/week at 40%-55% peak oxygen consumption)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 182
Study: 11392343

Group type: EXPERIMENTAL
Intervention: Amantadine (2.5 mg/kg per day for 1 week, then 5.0 mg/kg per day for 3 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9251847

Group type: EXPERIMENTAL
Intervention: 100 micrograms vaccine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 500 micrograms vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alum placebo
Number of subjects: 30
Study: 11767317

Group type: EXPERIMENTAL
Intervention: Pre-oxygenation with 8 litre min-1 oxygen through a plastic facemask for 3 min
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no pre-oxygenation)
Number of subjects: 60
Study: 2422927

Group type: EXPERIMENTAL
Intervention: Somatostatin intravenous drip (250 micrograms/h) for 4 hours, started at the beginning of operation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 20
Study: 29411251

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group (IG)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 180
Study: 27444119

Group type: EXPERIMENTAL
Intervention: Diet alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diet and drug treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: All interventions combined
Number of subjects: 60
Study: 24477028

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 522

Group type: COMPARATOR
Intervention: Non-pioglitazone
Number of subjects: 522
Study: 22625878

Group type: COMPARATOR
Intervention: Nutritional education intervention for caregivers, conducted by nurses with 4 home visits over 6 months.
Number of subjects: 200
Study: 20542419

Group type: EXPERIMENTAL
Intervention: 10% benzocaine gel (B10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: liposome‐encapsulated 10% benzocaine (LB10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20% benzocaine gel (B20)
Number of subjects: 30
Study: 18395396

Group type: EXPERIMENTAL
Intervention: Community-based evidence training by Lady Health Workers (LHWs) using new risk communication tools.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard procedures used by Lady Health Workers (LHWs) in the control group.
Number of subjects: 0
Study: 15538593

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14571352

Group type: EXPERIMENTAL
Intervention: CCK‐4 (N = 8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (N = 8)
Number of subjects: 24
Study: 12569689

Group type: EXPERIMENTAL
Intervention: rhEGF ointments of 10 micrograms/g
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (self-corresponding wounds of the same degree)
Number of subjects: 120
Study: 9713225

Group type: COMPARATOR
Intervention: Laser therapy alone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Laser followed by brachytherapy
Number of subjects: 26
Study: 8151900

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy plus continuing medical care (n = 328)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Medical care alone (n = 331)
Number of subjects: 659
Study: 3348613

Group type: EXPERIMENTAL
Intervention: Intravenous cefoperazone (2 g) and sulbactam (1 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cefoperazone (2 g) and sulbactam (1 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous dosing
Number of subjects: 6